England's community pharmacy network is smaller than it was five years ago, but the story is not one of uniform decline. NHSBSA's monthly Pharmacy Openings and Closures data shows independents adding NHS contracts every year since 2021, while the largest multiples have closed and rationalised their estates fast enough to shrink the total network anyway. For anyone buying, selling or valuing a pharmacy, that split, not just the headline total, is the number that matters.
This post covers England, where NHSBSA publishes the Pharmacy Openings and Closures dataset used throughout. Scotland (Public Services Scotland) and Wales (NWSSP) publish separate data not included here.
The headline: a network that is 815 pharmacies smaller than in 2021
As of the latest published NHSBSA release, England had 10,391 NHS-contracted community pharmacies in May 2026, down from 11,206 in January 2021.1 That is a net loss of 815 pharmacies over roughly five and a half years, and the network was down a further 11 sites year-on-year to May 2026.1 Excluding distance-selling (online-only) pharmacies, the total stood at 9,933.1
The Pharmacy Openings and Closures Index tracks this month by month. This post uses that index's totals throughout, drawn from NHSBSA's May 2026 release. A separate research asset on this site, the Pharmacy Density and Workload Index, draws on a different NHSBSA dataset pulled on a different date and can show a slightly different total pharmacy count as a result. The two are not directly comparable and should not be blended: this post's figures come specifically from the Pharmacy Openings and Closures dataset, cited throughout.
Independents and multiples are moving in opposite directions
NHSBSA segments every pharmacy by owner-group size: Small (1-5 premises), Medium (6-99) and Large (100+). Small-group is the cleanest public proxy for an independent; Large-group is the multiples. Since January 2021, those two segments have moved in opposite directions.1
| Snapshot | Total pharmacies | Small (1-5 premises) | Medium (6-99) | Large (100+) |
|---|---|---|---|---|
| January 2021 | 11,206 | 4,024 | 1,593 | 5,220 |
| December 2021 | 11,148 | 4,071 | 1,716 | 4,980 |
| December 2022 | 11,067 | 4,257 | 1,614 | 4,805 |
| December 2023 | 10,673 | 4,815 | 1,799 | 3,659 |
| December 2024 | 10,451 | 4,899 | 1,837 | 3,308 |
| December 2025 | 10,406 | 5,002 | 1,764 | 3,205 |
| May 2026 (latest) | 10,391 | 5,075 | 1,705 | 3,153 |
Small-group pharmacies grew from 4,024 to 5,075 over the period, a gain of over a thousand sites. Large-group pharmacies fell from 5,220 to 3,153, a loss of more than two thousand.1 Independents are not just holding share in a shrinking market, they are the only segment that has grown in absolute terms. Medium-group pharmacies (6-99 premises) took a different path again: they rose through 2021 to 2023, peaking at 1,892 in September 2023, before falling back to 1,705 by May 2026.1
Two smaller segments moved as well. Hundred-hour contract pharmacies, which commit to opening 100 hours a week in exchange for guaranteed market entry, fell from 1,096 to 785.1 Distance-selling (online-only) pharmacies rose from 369 to 458.1
A five-month window explains most of the multiples' contraction
The large-group decline was not a steady drift. NHSBSA's monthly opened and closed counts show it was heavily concentrated in a single window: between April and August 2023, large-group pharmacies recorded a net loss of 716 sites (monthly net changes of -133, -121, -137, -145 and -180 respectively).1 That is roughly a fifth of the entire five-year Large-group decline compressed into five months.
Small-group pharmacies moved the opposite way over the identical window, adding a net 356 sites (monthly net changes of 28, 51, 64, 83 and 130).1 Independents were opening and taking on contracts at the same time multiples were closing them fastest.
NHSBSA's dataset records only aggregate counts by owner-group size, not individual companies or their reasons for closing, and a change of ownership is recorded as a same-day closure and reopening rather than true market exit, so gross opened and closed figures overstate churn.1 What the net-change data supports is the shape of the event: a short, sharp estate rationalisation among the largest operators, not a gradual, evenly paced decline.
The corporate-formation data is moving the other way entirely
A second, independent public dataset adds context rather than contradiction. Companies House records incorporations against SIC code 47730 ('dispensing chemist in specialised stores'), and the count of new pharmacy-coded companies has risen sharply: from 227 in 2016 to 940 in 2025, a 314.1% increase (a 4.1x multiple) over the decade.2 As of 14 July 2026, 7,997 SIC 47730 companies were active on the register and 2,615 had been dissolved.2
This is a UK-wide count of corporate entities, not a count of England's dispensing premises, and it includes holding companies, group subsidiaries and online-only operators that may never hold an NHS contract.2 It is not a substitute for the NHSBSA contractor count, it is a different layer of the same market. And that layer has been diverging sharply from the physical network: SIC 47730 incorporations are up more than fourfold since 2016 while the number of NHS dispensing pharmacies has fallen in every one of those years.2
One month stands out on both spines at once. August 2023, the single worst month in the dataset for large-group net closures (-180), was also the peak month for SIC 47730 incorporations, with 186 new companies formed.12 The dataset does not identify which entities were involved, so this is an alignment worth noting rather than a proven causal link, but it fits a period of corporate restructuring running alongside the physical closures rather than two unrelated trends.
The formation trend has since cooled. Trailing-twelve-month incorporations to the last settled month (April 2026) stood at 802, down 18.2% year-on-year, against the 2025 annual total of 940.2 The most recent two months in the incorporation series are provisional pending Companies House indexing and are excluded from these figures.2
What a shrinking, more independent network means commercially
Three things follow from this data for anyone buying, selling or advising on a pharmacy transaction.
The pool of NHS contracts is smaller than it was, and it keeps shrinking. Because the NHS contract is the asset that drives a pharmacy's value, a market with 815 fewer contracts than five years ago is a market with less total goodwill available in aggregate, even where individual pharmacies are trading well. Scarcity does not automatically mean every contract is worth more, but it changes the competitive dynamic for buyers chasing a limited and falling number of opportunities.
More of that pool now sits with small operators, which changes who a buyer is dealing with. A market where independents hold a growing share is a market with more small-group sellers: owner-operators considering retirement or exit, rather than corporate divisions being carved out of a large estate. Due diligence on a small-group target still has to cover the same ground (FP34 history, Category M margin, VAT mix, TUPE), but the seller-side dynamics, and the goodwill negotiation that follows, tend to look different from buying a divested multiple site.
Buyer competition is not evenly spread across the network. The 2023 large-group contraction put a concentrated batch of sites onto the market in a short window; independents absorbed a large share of that supply, visible directly in the same-period small-group net gain. A shrinking network with a growing independent segment suggests continued appetite from small operators and consolidators to acquire, which is itself a data point when assessing what a specific opportunity is likely to attract in competing offers.
None of this changes the fundamentals covered in the pharmacy buyer's checklist: the contract, not the shop, is what is being valued, and structuring and financing decisions still have to be made on the specific target's numbers. What the network-level data adds is context: whether a specific deal sits inside a segment that is growing (small-group) or one that has been contracting hard (large-group), and what that implies for how much competition a listing is likely to attract.
Getting support with a pharmacy transaction
Network-level data is context, not a substitute for transaction-specific due diligence. If you are buying, selling or benchmarking a pharmacy against the current market, the buying a pharmacy hub and pharmacy owners hub cover the acquisition and ongoing finance picture in full, and the Pharmacy Openings and Closures Index is updated monthly on NHSBSA publication if you want to track how the split moves going forward. For a structured conversation about a specific transaction, get in touch.
Sources
- UK Community Pharmacy Openings and Closures Index, derived from NHSBSA Pharmacy Openings and Closures (resource: Pharmacy Openings and Closures - May 2026), Open Government Licence v3.0. Pulled 2026-07-23.
- UK Community Pharmacy Openings and Closures Index, derived from Companies House Advanced Search API (SIC 47730), Open Government Licence v3.0. Active/dissolved company snapshot as of 2026-07-14; incorporation series pulled 2026-07-23.